Eli Lilly and Company
Financial Performance
Eli Lilly Revenue & Financials
Revenue
$65.2B (FY2025)
Market Cap
$1.06T
Net Income
$20.6B
Employees
50,000
What is Eli Lilly's revenue?
Eli Lilly had $65.2B in revenue for fiscal year 2025, up 44.7% from 2024. Net income was $20.6B.
- Latest revenue
- $65.2B (FY2025)
- Year-over-year
- +44.7%
- Growth rate (CAGR)
- 15.1% over 9 years
- Peak revenue
- $65.2B (FY2025)
- Years of data
- 10
- Employees
- 50,000
- How much profit does Eli Lilly make?
- Eli Lilly reported net income of $20.6B for fiscal year 2025. sec.gov
- How many employees does Eli Lilly have?
- Eli Lilly has about 50,000 employees.
Financial Analysis
Revenue rose from $28.5 billion in 2022 to $45.0 billion in 2024 and $65.2 billion in 2025, while net income nearly doubled to $20.6 billion. Growth accelerated again in 2026: second-quarter revenue rose 48% to $23.0 billion, with Mounjaro at $9.94 billion (up 91%) and Zepbound at $4.93 billion. Lilly raised 2026 revenue guidance to $85-87 billion and non-GAAP EPS guidance to $35.50-36.50. Capital expenditures reached $7.8 billion in 2025 as Lilly expanded production capacity. Eli Lilly and Company is a pharmaceutical titan that has experienced massive growth, commanding a monumental market valuation frequently exceeding $700 billion.
Revenue Trend Analysis
YoY Change
+44.7%
9-Year CAGR
+15.1%
Peak Year
2025
Trend
Consistent Growth
Eli Lilly and Company has 10 full fiscal year figures on this page, compounding at +15.1% annually over 9 years. The most recent year saw a 44.7% increase versus the prior year. Annual revenue peaked in fiscal year 2025 at $65.2B. Of 9 comparable year-over-year steps, 9 showed growth and 0 showed a decline.
Annual revenue history
| Fiscal Year | Revenue | Net Income | YoY Change | Source |
|---|---|---|---|---|
| FY2025 | $65.2B | $20.6B | +44.7% | sec.gov 2025 revenue was $65.179B and net income was $20.640B. |
| FY2024 | $45B | $10.6B | +32.0% | data.sec.gov 2024 revenue was $45.043B as incretin demand accelerated. |
| FY2023 | $34.1B | $5.2B | +19.6% | data.sec.gov 2023 revenue was $34.124B. |
| FY2022 | $28.5B | $6.2B | +0.8% | data.sec.gov 2022 revenue was $28.5414B. |
| FY2021 | $28.3B | $5.6B | +15.4% | data.sec.gov 2021 revenue was $28.3184B. |
| FY2020 | $24.5B | $6.2B | +9.9% | Eli Lilly and Company annual report (Form 10-K, SEC EDGAR, filed 2023-02-22) Fiscal year ended 2020-12-31. |
| FY2019 | $22.3B | $8.3B | +3.8% | Eli Lilly and Company annual report (Form 10-K, SEC EDGAR, filed 2022-02-23) Fiscal year ended 2019-12-31. |
| FY2018 | $21.5B | $3.2B | +7.6% | ELI LILLY AND COMPANY annual report (SEC EDGAR, filed 2020-02-19) Fiscal year ended 2018-12-31. Figure as presented in the annual report filed 2020-02-19. |
| FY2017 | $20B | -$204.1M | +9.1% | ELI LILLY AND COMPANY annual report (SEC EDGAR, filed 2020-02-19) Fiscal year ended 2017-12-31. Figure as presented in the annual report filed 2020-02-19. |
| FY2016 | $18.3B | — | — | Wikidata total revenue statement, citing the linked document |
Click any row to see year details.
Eli Lilly and Company balance sheet and cash flow
Balance-sheet figures are as of each fiscal year end; cash-flow figures cover the fiscal year. Taken from the company's annual report on Form 10-K, linked on each row.
| Fiscal Year | Operating cash flow | Total assets | Shareholders' equity | Source |
|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $16.8B | $112.5B | $26.5B | Form 10-K |
| FY2024ended Dec 31, 2024 | $8.8B | $78.7B | $14.3B | Form 10-K |
| FY2023ended Dec 31, 2023 | $4.2B | $64B | $10.8B | Form 10-K |
| FY2022ended Dec 31, 2022 | $7.6B | $49.5B | $10.6B | Form 10-K |
| FY2021ended Dec 31, 2021 | $7.4B | $48.8B | $9B | Form 10-K |
| FY2020ended Dec 31, 2020 | $6.5B | $46.6B | $5.6B | Form 10-K |
| FY2019ended Dec 31, 2019 | $4.8B | $39.3B | $2.6B | Form 10-K |
| FY2018ended Dec 31, 2018 | $5.5B | $43.9B | $9.8B | Form 10-K |
| FY2017ended Dec 31, 2017 | $5.6B | $45B | $11.6B | Form 10-K |
Keep researching Eli Lilly
Eli Lilly Revenue and Financial FAQ
What is Eli Lilly's annual revenue and market capitalization?
Eli Lilly and Company reported revenue of $65.2 billion for fiscal year 2025, up from $45.0 billion in fiscal 2024, and had a market capitalization of about $1.06 trillion as of September 29, 2026.
What are Eli Lilly's gross profit margins and operating cash flows?
Due to its patented biopharmaceutical portfolio and high manufacturing yield, Eli Lilly reported a gross margin of 83.0% of revenue in 2025 (81.3% in 2024) and generated $16.8 billion of operating cash flow in 2025, up from $8.8 billion in 2024.
What is Eli Lilly's dividend policy and shareholder return track record?
Eli Lilly has paid consecutive dividends every year since 1885 (140 consecutive years), delivering a 10-year dividend CAGR exceeding 15% and systematically increasing its quarterly cash dividend per share.
What is Eli Lilly's credit rating and balance sheet profile?
Eli Lilly maintains one of the highest credit ratings in global corporate finance (A1 from Moody's and A+ from S&P Global), managing a conservative debt profile with fixed-rate senior notes and strong liquidity.
What is the revenue growth rate of Mounjaro and Zepbound?
Mounjaro and Zepbound have delivered historic triple-digit year-over-year revenue growth, rapidly becoming multi-billion-dollar quarterly blockbusters as manufacturing supply expands to meet surging global physician demand.
What percentage of Eli Lilly's revenue is generated internationally outside the US?
About 33% of Lilly's 2025 revenue ($21.7 billion of $65.2 billion) was generated outside the United States, reflecting major commercial operations across Europe, Japan, China, Latin America, and the Middle East.
How much does Eli Lilly invest in manufacturing capital expenditures (CapEx)?
Eli Lilly spent $7.8 billion on property and equipment in 2025, up from $5.1 billion in 2024, to construct automated sterile injectable filling lines, autoinjector assembly plants, and active pharmaceutical ingredient (API) chemical synthesis facilities.
How does Eli Lilly manage patent expiration cliffs?
Lilly manages patent expiries by continuously advancing a strong clinical pipeline of next-generation therapies (such as replacing Trulicity with Mounjaro, and launching Verzenio and Kisunla), ensuring sustainable revenue replacement.
Why did Eli Lilly stock go up so much?
In the 2020s, Eli Lilly's financial valuation absolutely exploded due to the massive, unprecedented success of their GLP-1 agonist drugs (Mounjaro and Zepbound). These drugs cause massive weight loss, creating what Wall Street believes could be the best-selling pharmaceutical product in human history.
Cite or embed this data
Using these figures? Please credit CorpDigest with a link.
CorpDigest. "Eli Lilly Revenue & Financials." CorpDigest, https://corpdigest.com/company/eli-lilly/financials.<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>Eli Lilly reported $65.2B in revenue (FY2025).</strong><br>Source: <a href="https://corpdigest.com/company/eli-lilly/financials" target="_blank" rel="noopener">CorpDigest — Eli Lilly financials</a></div>Related Financial Audits
Compare revenue, net income, and market cap scale
Explore Eli Lilly
Core profile pages, founders and related research hubs for this company.